期刊
MOLECULAR THERAPY
卷 7, 期 6, 页码 748-754出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/S1525-0016(03)00092-3
关键词
oncolytic; herpes simplex virus; late viral promoter; fusogenic membrane glycoprotein; liver cancer
资金
- NCI NIH HHS [P50CA058204, R01 CA85931] Funding Source: Medline
Oncolytic viruses have shown considerable promise in the treatment of solid tumors, but their potency must be improved if their full clinical potential is to be realized. We inserted the gene encoding a truncated form of the gibbon ape leukemia virus envelope fusogenic membrane glycoprotein (GALV.fus) into an oncolytic herpes simplex virus, using an enforced ligation procedure. Subsequent in vitro and in vivo studies showed that expression of GALV.fus in the context of an oncolytic virus significantly enhances the antitumor effect of the virus. Furthermore, by controlling GALV.fus expression through a strict late viral promoter, whose activity depends on the initiation of viral DNA replication, we were able to express this glycoprotein in tumor cells but not in normal nondividing cells. It will be of interest to confirm whether functional expression of a strong fusogenic gene by an oncolytic herpes simplex virus enhances viral antitumor activity without increasing its toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据